Boston Sci explains its top-down restructuring

Boston Scientific is shedding more light on a top-down restructuring that has seen it realign or replace more than 75 percent of its top 50 senior managers in the past year. "We've spent a lot of time thinking about what the senior management team needs to be," BSX CFO Jeff Capello said at the Barclay's Capital 2011 Global Healthcare Conference. "The senior management team that's rejuvenated is in place." The company has also realigned its compensation program, reducing short term compensation and creating a broader employee stock purchase program, Capella added. Report

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.